ASP Isotopes Stock Price, News & Analysis

ASP Isotopes (NASDAQ: ASPI), a company focused on developing technology for isotope production across multiple industries, has announced an upcoming investor webcast scheduled for Tuesday, May 20, 2025, at 8:00 a.m. EST. Investors can access the webcast through a Zoom link, and a recording will be available on the company's investor relations website for at least 90 days following the event.

ASP Isotopes (NASDAQ: ASPI) has entered into multiple definitive agreements with TerraPower, including a loan agreement and supply contracts for High Assay Low-Enriched Uranium (HALEU). The company will construct a new uranium enrichment facility at Pelindaba, South Africa, designed to produce approximately 15 MTU of HALEU annually. The facility is expected to begin production in 2027. The agreements include a supply contract for TerraPower's Natrium project in Wyoming and a 10-year supply agreement for up to 150 metric tons of HALEU from 2028 through 2037. ASPI will utilize its proprietary Aerodynamic Separation Process and Quantum Enrichment Process technologies, which the company claims can be deployed with lower capital costs and faster implementation compared to traditional methods.

ASP Isotopes (NASDAQ: ASPI) has announced plans for a secondary listing on the Johannesburg Stock Exchange (JSE) while maintaining its Nasdaq Capital Market listing. The company, focused on isotope production technology, has strong ties to South Africa with 97% of employees and all operating facilities located there.

ASPI operates three plants in Pretoria, developing commercial production of Carbon-14, Silicon-28, and Ytterbium-176 for pharmaceutical, medical, quantum computing, and semiconductor applications. The JSE listing, expected later in 2025 subject to regulatory approvals, aims to enhance shareholder liquidity, diversify the investor base, and access additional capital markets.

The company has appointed Valeo Capital Proprietary as the sole South African Corporate Advisor and JSE Sponsor for the listing process.

ASP Isotopes (NASDAQ: ASPI) announced significant board changes and strategic restructuring plans. Sipho Maseko, former CEO of Telkom SA and MD of Vodacom SA, has joined ASPI's board of directors, while Dr. Hendrik Strydom has transitioned from ASPI's board to Quantum Leap Energy 's (QLE) board of managers.

The company plans to separate into two independent public companies during 2H 2025: the Nuclear Fuels business (QLE) and the Specialist Isotopes and Related Services business. The separation aims to address different regulatory landscapes, supply chains, and funding requirements. QLE's board currently includes Paul Mann as Chairman and CEO, Michael Gorley, Ph.D., Duncan Moore, Ph.D., and Dr. Strydom.

Additionally, ASPI granted restricted stock awards to three new non-executive employees, totaling 250,000 shares vesting over four years in eight semi-annual installments.

ASP Isotopes (NASDAQ: ASPI) has successfully commissioned its first Quantum Enrichment laser system in Pretoria, South Africa, and begun producing commercial samples of Ytterbium-176. The facility, completed in 8 months instead of the planned 18 months, represents the company's third enrichment facility in South Africa and first using Quantum Enrichment technology.

The company expects to achieve 99.75% enrichment for Ytterbium-176 and begin commercial sales in 2025. This isotope is important for producing Lutetium-177, used in oncology drugs like Novartis' Pluvicto, which has a market forecast exceeding $4 billion.

Following this success, ASPI is accelerating plans to construct facilities for Nickel-64, Gadolinium-160, and Lithium-6/7 enrichment. The company is also pursuing discussions with nuclear authorities regarding HALEU uranium enrichment facilities, addressing an estimated supply shortage of 3,000 metric tons by 2035, with potential customer demand valued at over $37 billion.

ASP Isotopes (NASDAQ: ASPI) has scheduled the release of its fourth quarter and fiscal year 2024 financial results on March 31, 2025, after market close. The company will host a follow-up webinar on April 1, 2025, at 10:00 am ET (3:00 pm UK time, 4:00 pm South African time).

Chairman and CEO Paul Mann will lead the webinar presentation, providing a comprehensive review of the company's financial and operational performance for 2024, along with insights into corporate strategies and outlook for 2025.

ASP Isotopes (NASDAQ: ASPI) has initiated commercial production of enriched Silicon-28 at its second Aerodynamic Separation Process facility in Pretoria, South Africa. The company's proprietary technology enriches silane (SiH4) directly, potentially offering higher quality output compared to competitors' methods that require additional chemical conversion processes.

Silicon-28 is important for quantum computing and next-generation semiconductors, offering two key advantages: it's spin-free, protecting qubits from decoherence, and can conduct heat 150% more efficiently than natural silicon, enabling smaller, faster, and cooler chips.

ASPI has secured two purchase agreements with US-based customers (a semiconductor company and an industrial gas company) for kilogram quantities of Silicon-28. The company expects to ship its first commercial batches in Q2 2025 and is in discussions with multiple global customers for additional supply agreements in the next six months.

ASP Isotopes (NASDAQ: ASPI) has initiated commercial production of enriched Carbon-14 at its first Aerodynamic Separation Process (ASP) facility in Pretoria, South Africa. The company expects to begin shipping products by mid-2025. A multi-year take-or-pay contract with Canadian customer RC-14 Inc. is valued at minimum $2.4 million annually.

The facility's commercial production, initially planned for 2024, faced delays due to international shipping complications affecting specialized feedstock supply. Carbon-14, primarily used as a radiolabel in drug discovery and metabolism studies, has historically been exclusively supplied by Russia, with existing shortages intensified by recent global disruptions.

ASP Isotopes (NASDAQ: ASPI) has announced its participation in the Canaccord Genuity Sustainability Summit on Wednesday, February 26, 2025. This virtual event will feature presentations, panel discussions, and one-on-one meetings with company executives and industry experts.

Paul Mann, Chairman and Chief Executive Officer of ASP Isotopes, will join a panel discussion on the future of nuclear fission from 9:30-10:10 a.m. Eastern Time. The panel will also include Jeffrey Miller, Vice President of Business Development at TerraPower, and Christopher Colbert, Chief Executive Officer of Elementl Power.

ASP Isotopes, an advanced materials company focused on developing technology for isotope production across multiple industries, invites institutional investors to attend the virtual event by contacting their Canaccord Genuity representative.